Application of the in silico approach in the study of critical genes predicting chemotherapeutic response to oxaliplatin in treatment of prostate cancer (literature reviev)

Author:

Loginova M. V.1ORCID,Pavlov V. N.2ORCID,Gilyazova I. R.3ORCID

Affiliation:

1. Republican Clinical Oncology Dispensary, Ministry of Health of the Republic of Bashkortostan

2. Bashkir State Medical University, Ministry of Health of Russia

3. Bashkir State Medical University, Ministry of Health of Russia; Ufa Federal Research Center of the Russian Academy of Sciences

Abstract

Prostate cancer is the leading cause of death among men. Existing prognostic factors make it possible to differentiate the degree of malignancy of tumors with high metastatic potential. Currently, the treatment of high-grade tumors is carried out with hormonal therapy, to which taxanes are added, when the malignant neoplasm becomes resistant to castration. Studies with other anti-cancer agents did not take into account the genetic background of the tumors, and most of the trials showed low response rates. The article describes an in silico approach for screening drug candidates that can be used as an alternative to taxanes. Researched 86 genes that distinguish between high and low grade tumors, and identified several genes that correlated with chemosensitivity. As an example, a set of six genes has been proposed the expression levels of which can predict cell sensitivity to oxaliplatin. The study demonstrates the relevance of an approach to the treatment of high-grade prostate cancer and new biomarkers for predicting clinical tumor response.

Publisher

Publishing House ABV Press

Subject

Urology,Nephrology,Radiology Nuclear Medicine and imaging,Oncology,Surgery

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3